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Michele Kohli1*, Donna Lawrence1, Jennifer Haig1, Andrea Anonychuk2 and Nadia Demarteau2Background: In Canada, two vaccines that have demonstrated high efficacy against infection with human
papillomavirus (HPV) types −16 and −18 are available. The HPV-6/11/16/18 vaccine provides protection against
genital warts (GW) while the HPV-16/18 vaccine may provide better protection against other oncogenic HPV types.
In this analysis, the estimated clinical and economic benefit of each of these vaccines was compared in the
Canadian setting.
Methods: A Markov model of the natural history of HPV infection among women, cervical cancer (CC) and GW was
used to estimate the impact of vaccinating a cohort of 100,000 12-year-old females on lifetime outcomes and
healthcare system costs (no indirect benefit in males included). A budget impact model was used to estimate the
impact of each vaccine by province.
Results: In the base case, vaccination with the HPV-16/18 vaccine was predicted to prevent 48 additional CC cases,
and 16 additional CC deaths, while vaccination with the HPV-6/11/16/18 vaccine was predicted to prevent 6,933
additional GW cases. Vaccination with the HPV-16/18 vaccine was estimated to save 1 additional discounted quality
adjusted life year (QALY) at an overall lower lifetime cost to the healthcare system compared to the HPV-6/11/16/18
vaccine (assuming vaccine price parity). In sensitivity analyses, the HPV-6/11/16/18 vaccine was associated with
greater QALYs saved when the cross-protection efficacy of the HPV-16/18 vaccine was reduced, or the burden of
GW due to HPV-6/11 was increased. In most scenarios with price parity, the lifetime healthcare cost of the strategy
with the HPV-16/18 vaccine was predicted to be lower than the HPV-6/11/16/18 vaccine. In the probabilistic
sensitivity analyses, the HPV-16/18 vaccine provided more QALY benefit than the HPV-6/11/16/18 vaccine in 49.2%
of scenarios, with lower relative lifetime costs in 83.5% of scenarios.
Conclusions: Overall, the predicted lifetime healthcare costs and QALYs saved by implementing each of the
vaccines are similar. Vaccination with the HPV-16/18 vaccine is expected to be associated with reduced CC disease
morbidity and mortality compared to vaccination with the HPV-6/11/16/18 vaccine. Differences in these outcomes
depend on the extent of cervical disease prevented by cross-protection and the burden of GW caused by HPV-6/11.
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Fifteen of the approximately 40 human papillomavirus
(HPV) genotypes that infect the human anogenital area
are known to be oncogenic [1]. While most HPV infec-
tions are self-limiting and resolve within 24 months, per-
sistent HPV infection with an oncogenic type is the
predominant cause of cervical cancer [2], the third most
common cancer in women worldwide [3]. HPV types
−16 and −18 account for approximately 70% of cervical
cancer cases [4], while other oncogenic HPV types, in-
cluding HPV-31, -33, -35, -39, -45, -51, -52, -56, -58,
-59, -66 and −68, are involved in the remainder[5]. Of
note, HPV-31 and −45 account for an additional 10% of
cervical cancers worldwide [6] while HPV-16, -18 and
−45 account for over 90% of adenocarcinomas [7]. Low-
risk HPV genotypes, such as HPV-6 and −11, do not
cause cancer but can lead to genital warts and low-grade
pre-cancerous lesions [8].
In Canada, secondary prevention of cervical cancer
through opportunistic and organized screening has
reduced the burden of disease relative to other countries
[9]. However, despite screening, approximately 1,300
Canadian women are still diagnosed with cervical cancer
and 370 die from the disease each year [10]. Vaccination
to prevent HPV infection is regarded as an effective
strategy for controlling HPV-related diseases. In 2007,
the Canadian Immunization Committee (CIC) recom-
mended that “school-based HPV vaccination of one fe-
male cohort be implemented in all Canadian provinces
and territories” [1]. The CIC set goals to reduce cervical
intraepithelial neoplasia (CIN) 2/3, cervical cancer inci-
dence, and cervical cancer related deaths by 60% over
the next 20 to 35 years and to increase vaccine coverage
up to 90% within five years of introduction of the pro-
gram. All provinces had introduced school-based
immunization programs by the 2008/09 school year tar-
geting one age group, ranging from grades 4 to 8
(Table 1). Five provinces also implemented temporary
catch-up vaccination programs in older age groups
(Table 1).
Two HPV vaccines are currently available in Canada:
a HPV-6/11/16/18 vaccine (Gardasil®, developed by
Merck) has been licensed since July 2006, and a HPV-
16/18 AS04-adjuvanted vaccine (Cervarix®, manufac-
tured by GlaxoSmithKline), was approved in February
2010. Both vaccines provide excellent protection against
HPV-16 and −18 and their related cervical outcomes.
The HPV-6/11/16/18 vaccine is a quadrivalent vaccine
that also provides protection against non-oncogenic
HPV types −6 and −11 which can cause genital warts and
CIN1. The HPV-16/18 AS04-adjuvanted vaccine has a
proprietary AS04 adjuvant system which has been shown
to enhance humoral and B cell responses compared to
the same antigens adjuvanted with aluminium [24].Cross-protection is the ability to prevent infection
with oncogenic HPV types not contained in the vac-
cine. In clinical trials, the HPV-16/18 AS04-adjuvanted
vaccine provided 100% (96.1% CI, 82.2 to 100) cross-
protection against CIN2+ caused by HPV-31/45 and
68.4% (96.1% CI, 45.7 to 82.4) efficacy against CIN2+
caused by the 10 most common non-vaccine onco-
genic HPV types (−31, -33, -35, -39, -45, -51, -52, -56,
-58, -59) in an HPV-naïve population [25,26]. In a sep-
arate trial of HPV-naïve young women, the HPV-6/11/
16/18 vaccine reduced CIN2/3/adenocarcinoma in situ
(AIS) associated with HPV-31/45 by 58.7% (95% CI,
14.1 to 81.5) and CIN2/3/AIS associated with the same
10 HPV types by 32.5% (95% CI, 6.0 to 51.9) [27]. The
majority of non-16/18 cervical cancers and CIN2/3
precancerous lesions, plus a proportion of CIN1 cases,
are caused by these non-vaccine oncogenic HPV types.
Therefore, greater cross-protection should translate
into additional cases of CIN1, CIN2/3 and cervical
cancer prevented. A dose of the HPV-6/11/16/18 vac-
cine is recommended to be administered at months 0,
2 and 6 [28], while a dose of the HPV-16/18 AS04-
adjuvanted vaccine is recommended to be administered
at 0, 1 and 6 months [29].
Economic modeling studies have consistently pre-
dicted that the adoption of HPV vaccination programs
to prevent cervical cancer are economically attractive. In
Canada, published analyses have found that HPV vaccin-
ation plus screening for cervical cancer is cost-effective
compared to use of a screening program alone, with in-
cremental cost-effectiveness ratios (ICERs) varying from
approximately $18,000 – $32,000 per quality adjusted
life year (QALY) gained in the base case analyses [30-
33]. Only one of these published cost-effectiveness stud-
ies assessed the additional benefit associated with cross-
protection against non-vaccine oncogenic HPV types.
Anonychuk et al. [30] modeled a cohort of 100,000 12-
year-old females vaccinated with the HPV-16/18 AS04-
adjuvanted vaccine over a lifetime, using an economic
model which included cross-protection and herd im-
munity. Results showed additional reductions in cervical
cancer cases and deaths associated with cross-protec-
tion, and hence, demonstrated more economically at-
tractive cost-effectiveness ratios.
A few published economic analyses have directly com-
pared the HPV-16/18 AS04-adjuvanted and HPV-6/11/
16/18 vaccines resulting in discordant conclusions.
Those comparisons that did not consider the additional
benefit of cross-protection concluded that the HPV-6/
11/16/18 vaccine provides better value for money than
the HPV-16/18 AS04-adjuvanted vaccine due to the
additional costs saved and QALY gained by preventing
genital warts attributed to HPV-6 and −11 [33-37].
The comparisons that included cross-protection have
Table 1 Overview of provincial vaccination program policies and target population inputs for the budget impact
analysis












British Columbia Grade 6 2008-09 11 years 66% [12]a 24 027 15 858
2008 – 2010 Only: Grade 9
Catch-up program [11] 2+1
Dosing strategy used
Alberta Grade 5 2008-09 10; 14; 15; 16 years 50%a 10 years: 19 489 10 years: 9 745
Sept 2009 to June 2012 Only:
Age 14–16 years Catch-up
program [13]
14 years: 21 967 14 years: 10 984
15 years: 22 563‡ 15 years: 5 790
16 years: 22 969 ‡ 16 years: 3 060
Saskatchewan Grade 6 or beyond with a
date of birth no earlier than
January 1, 1996. [14]
2008-09 11 years 85%a 5 652 4 760
Manitoba Grade 6 [15] 2008-09 11 years 55%a 6 504 3 577
Ontario Grade 8 [16] 2007-08 13 years 53% [17]a 74 048 39 246
Quebec Grade 4 (2-dose in Grade 4
with booster in Grade 9)
Grade 9 catch-up [18]
2008-09 9 years 76% [19] 9 years: 40 099 9 years: 30 476
14 years 14 years: 46 756 14 years: 35 534
Newfoundland
and Labrador
Grade 6[20] 2008–10 Only:
Grade 9 catch-up cohort
2007-08 11 years 83%a 2 710 2 249
New Brunswick Grade 7, 2008-09 12 years 85%a 4 080 3 468
2008–09 Only: Grade 8
catch-up [21]
13 years (2008 Only)
Nova Scotia Grade 7 [22] 2007-08 12 years 80% [17]a 5 192 4 154
Prince Edward Island Grade 6 [23] 2007-08 11 years 80% [17]a 723 578
* Women in the catch-up program are assumed to receive the same number of doses as those in the primary target population. Unless stated that a 2+1 dosing
schedule is recommended, the provinces have adopted the recommended 3-dose schedule for the vaccines.
† The catch-up programs may have been initiated after the primary vaccination program began or implemented in selected school years only. For this analysis,
only catch-up programs in the 2011/12 school year were modelled.
‡ In order to determine the number of women eligible for vaccination, the budget impact model calculates the number of women vaccinated since the
implementation of the vaccination program in each province. Although there are expected to be 22 563 15-year olds and 22 969 16-year olds in Alberta in 2011,
10 983 and 16 849 respectively are expected to be vaccinated prior to the 2011/12 school year. Therefore, only 11 580 15-year olds and 6 120 16-year olds are
eligible for the catch-up program targeting these age groups.
a Coverage estimated by local experts unless otherwise specified.
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impact on cancer outcomes and cost-effectiveness
[38,39]. Demarteau et al. [40] examined the hypothetical
difference in cross-protection efficacy needed for a vac-
cine with a profile similar to the HPV-16/18 AS04-
adjuvanted vaccine to be cost-effective when compared
with a vaccine similar to the HPV-6/11/16/18 vaccine
in the settings of France, Ireland and Italy. Their
discounted results predicted that the HPV-16/18
AS04-adjuvanted vaccine would be more economically
attractive than the HPV-6/11/16/18 vaccine when the
former provided an additional 22% cross-protection ef-
ficacy against 10 HPV types. Jit et al. [41] examined
the impact of both vaccines in the United Kingdom.
Although they concluded that the HPV-16/18 AS04-
adjuvanted vaccine prevented additional cervical cancer
cases, the HPV-6/11/16/18 vaccine’s ability to prevent
genital warts saved more QALYs and health care costs
than additional cross-protection with the HPV-16/18
AS04-adjuvanted vaccine.Calculation of the incremental costs and benefits of a
new intervention relative to existing health care strat-
egies allows determination of efficiency or value for
money. Decision makers are also concerned about the
intervention’s impact on their budget because a new
technology may be efficient but not affordable. It is also
important for decision makers to understand the abso-
lute clinical impact of a new intervention within their
population. Budget impact models are often constructed
to help quantify the number of people eligible for a new
intervention as well as the costs of that new intervention
in a particular jurisdiction [42].
The first objective of this analysis was to estimate
the relative clinical and economic benefit of the HPV-
16/18 AS04-adjuvanted vaccine compared with the
HPV-6/11/16/18 vaccine in the Canadian setting while
considering cross-protection efficacy. The second ob-
jective was to look at the clinical and cost impact of
implementing each vaccine within each of the 10 Can-
adian provinces.
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This study used a previously published static Markov
model that reproduced the natural history of oncogenic
HPV with a one year cycle length [30,32]. Previous ver-
sions of this model simulated CIN1, CIN2/3, and cancer
associated with oncogenic HPV types. This updated ver-
sion includes non-oncogenic (low-risk) HPV infections,
CIN1 disease due to non-oncogenic HPV infections, and
genital warts (Figure 1) [40]. The model vaccine efficacy
calculations, detailed by Debicki and colleagues [32],
allow specification of the proportion of HPV types −16
or −18, non-vaccine oncogenic HPV types and HPV
types −6 and −11 within all lesions, as well as vaccine ef-
ficacy by infection and lesion type.
The model was developed in Microsoft® Excel 2007
and simulates the effect of adding vaccination to the
current screening program, where two cohorts of
100,000 12-year-old females were followed over a life-
time, one cohort vaccinated with the HPV-16/18 AS04-
adjuvanted vaccine and the other with the HPV-6/11/
16/18 vaccine. The model was previously calibrated to
reproduce Canadian cervical cancer incidence and mor-
tality, while keeping transition probabilities within pre-
determined ranges [30,32]. The incidence of cervical













Figure 1 Overview of the cohort model. NoHPVonc: Women in this hea
health state have a low risk (non-oncogenic) HPV infection. HPVonc: Wom
Women in this health state have developed cervical intraepithelial neoplas
Women in this health state have genital warts. CIN1lr: Women in this heal
type. CIN23: Women in this health state have developed CIN2/3 due to an
each of the health states whose cervical disease is detected through screenmodel calibration was updated as shown in Figure 2 to
reflect the latest Canadian cervical cancer incidence data
[43] and published genital warts incidence data [44].
Table 2 summarizes the base case model inputs. The
model was parameterized using Canadian-specific screen-
ing, economic, and epidemiological data where available,
as well as expert opinion. All events were costed from the
perspective of the health care system in 2006 dollars. The
incidence and cost per case of genital warts was obtained
from analysis of an administrative databases in British
Columbia, Canada [44]. The remaining data comes from
the previously published Canadian analysis [30], with the
exception of the distribution of HPV types within the
health states displayed in Table 3. These distributions were
updated to reflect a recent World Health Organization
(WHO) review of Canadian data [45]. As vaccine coverage
rates do not impact the cost-effectiveness ratios estimated
with a static model, a coverage rate of 100% was assumed.
A 98% vaccine efficacy against HPV types 16 and 18 was
used based on the latest results from each vaccine’s clinical
trials [25,27,47,49,50,62-66]. For the HPV-16/18 AS04-
adjuvanted vaccine, 47.7% (96.1% CI: 28.9- 61.9) and
68.4% (96.1% CI: 45.7-82.4) cross-protective efficacy
against CIN1+ and CIN2+, respectively, was demon-







lth state have no oncogenic HPV infection. HPVlr: Women in this
en in this health state have an oncogenic HPV infection. CIN1onc:
ia (CIN)1 due to an infection with an oncogenic HPV type. Wart:
th state have developed CIN1 due to an infection with a low risk HPV




































































Observed Incidence (Marra et al 2009)
B
Figure 2 Validation of the model. Panel A shows the model predicted cervical cancer incidence per 100,000 women compared to reported
data from Canada in 2007 [43]. Panel B shows the model predicted genital warts incidence compared to data reported by Marra et al. [44].
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−59 in clinical trials [25]. For the HPV-6/11/16/18 vaccine,
23.4% (95% CI: 7.8 to 36.4) and 32.5% (95% CI: 6.0-51.9)
cross-protective efficacy against CIN1+ and CIN2+ re-
spectively for the same 10 non-vaccine oncogenic HPV
types [27] was demonstrated in clinical trials. These effi-
cacy values come from two independent studies that re-
port efficacy values for an HPV-naïve population in a
similar manner for the same HPV types. In this analysis,the observed reduction in CIN1+ was input as efficacy
against CIN1, while the observed reduction in CIN2+ was
input as efficacy against CIN2/3 and cervical cancer out-
comes. A 98% vaccine efficacy against HPV types −6 and
−11 was assumed for the HPV-6/11/16/18 vaccine based
on clinical trial data [49,50]. This analysis assumed life-
long protection against all HPV types, including cross-
protection against non-vaccine types. Both of the vaccines
were assumed to cost $100 per dose plus an
Table 2 Key base case cost-effectiveness model inputs
Input parameters Base case value References
Vaccination
Duration of vaccine protection Lifetime Assumption
Age at Vaccination (years) 12 Assumption
Vaccine Coverage 100% Assumption
Efficacy: HPV-16/18 (both vaccines) 98.0% [26,46-50]
HPV-16/18 AS04-adjuvanted Vaccine
Efficacy: Non-vaccine oncogenic HPV types
CIN1 47.7% (95% CI: 28.9%, 61.9%) [51]
CIN2+ 68.4% (95% CI: 45.7%, 82.4%) [25]
HPV-6/11/16/18 vaccine Efficacy: Non-vaccine oncogenic HPV types [27]
CIN1 23.4% (95% CI: 7.8%, 36.4%)
CIN2+ 32.5% (95% CI: 6.0%, 51.9%)
HPV-6/11/16/18 Vaccine Efficacy: HPV 6/11 98.0% [50]
Screening
Screening Coverage [52]
Age Range 18 to 69 years
Regular (once/ 3 years) 70%
Irregular (ages 25, 40, 50) 18%
Never 12%
CIN1 detected (sensitivity) 42% [44,52,53]
CIN2/3 detected (sensitivity) 55% [44,52,53]
% Positive pap Smear 5% [44,52,53]
Cost (2006 CAD)
HPV-16/18 AS04-adjuvanted vaccine Cost (per dose) $110.97 Assumption
HPV-6/11/16/18 vaccine Cost (per dose) $110.97 Assumption
Genital Warts treatment (per episode) $207.00 [44]
Cytology Test $57.00 [30,33,54]
Colposcopy and biopsy $150.00 [30,33,54]
CIN1 treatment and follow-up* $843.00 [30,33,54]
CIN2/3 treatment and follow-up* $1 414.00 [30,33,54]
Cervical cancer stage 1 $11 915.00 [30,33,54]
Cervical cancer stage 2 $18 851.00 [30,33,54]
Cervical cancer stage 3 $18 851.00 [30,33,54]
Cervical cancer stage 4 $25 759.00 [30,33,54]
Utility
No HPV, HPV Infection 1, 1
CIN1 detected 0.987 [55-58]
CIN2/3 detected 0.991 [55-58]
Cancer treated 0.727 [55-58]
Cancer cured 0.938 [55-58]
Genital Warts 0.980† [59]
* Cost calculated assuming that 50% of CIN1 and 100% of CIN2/3 are treated. Follow-up after CIN1/2/3 assumed to include 2 additional cytology tests and
colposcopies for all patients.
† Genital warts assumed to cause a decrement of 0.8 in utility across 3 months.
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16/18 24.9% [45] 24.9% 25.6% 22.0% [60]
CIN1 CP* 33.6% 33.6% 67.5% 57.0%
6/11 4.8% 4.8% 7.6% 6.0%
Other 6.9% 36.7% 17.8% 15.0%
16/18 56.2% [45] 56.2% 55.2% 50.0% [60]
CIN2/3 CP* 32.9% 32.9% 49.6% 45.0%
Other 2.5% 10.9% 5.6% 5.0%
16/18 74.3% [45] 74.3% 76.5% 85.0% [60]
Cancer CP* 18.3% 18.3% 13.6% 15.0%
Other 2.2% 7.4% 1.0% 0.0%
Genital Warts 6/11 [61] 76.2% 76.2% [61]
* CP: Cross-protection – oncogenic HPV types affected by the vaccine: HPV-31,-33,-35,-39,-45,-51,-52,-56,-58,-59.
† The proportion in the other HPV category was increased as required so that all cervical outcomes were associated with an HPV infection.
‡ The sum of proportions of all HPV infections were equal to more than 100% for CIN1 and CIN2/3 lesions due to multiple HPV infections. For modelling purposes,
the values in each HPV category were proportionally reduced so that sum of all HPV types equals 100% .
CC – Cervical cancer.
CIN – Cervical Intraepithelial Neoplasia.
HPV – Human papillomavirus.
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3 doses were given for both [28,29]. For the cost-
effectiveness analysis, it was assumed that the entire co-
hort received all doses (100% coverage). Since this model
is a static cohort model, it does not estimate the impact of
reduced transmission of virus from women to men and
any accompanying indirect benefit to men.
The lifetime number of CIN lesions, cervical cancer
cases, cervical cancer related deaths, genital warts cases,
QALYs, and costs were determined for each cohort. An
ICER (cost per QALY gained) was calculated to compare
the costs and outcomes of the two vaccines. A discount
rate of 3% was applied to both costs and outcomes.
A number of sensitivity analyses were conducted by vary-
ing inputs assumed to impact the relative value of the two
vaccines. The HPV-6/11/16/18 vaccine’s price per vaccine
dose was varied to determine the point at which both vac-
cines would be predicted to have equivalent lifetime costs
to the health care system. In a series of two-way sensitivity
analyses, the efficacy of each vaccine against CIN2+ out-
comes associated with non-vaccine oncogenic types was
varied using the confidence intervals from the clinical trials.
In addition, alternative WHO data for the continent of
North America was used to populate the distribution of
HPV types within cervical health states [68,69]. The overall
impact of genital warts was tested with a series of one way
sensitivity analyses varying the costs of genital warts (±25%),
the quality of life impact (measured as a utility decrement)
of genital warts (±25%; QALY decrement increased from
0.02 in base case to 0.041 [Maximum decrement observed
in recent publications] [70,71]), and the incidence of genital
warts (±10%; ±25%). The proportion of genital warts attrib-
uted to HPV types - 6 and - 11 was increased to 90% fromthe base case of 76%. Finally, simulation studies with trans-
mission models have estimated that protecting females from
HPV-6 / -11 may also reduce infection levels in males by as
much as 90% over the next 70 years due to herd immunity
[72]. Consistent with those predictions, Donovan et al. re-
port an observed decrease in genital warts of 39% (95% CI
33–46; p trend <0.0001) in males aged 12 – 26 years in
Australia since implementation of the quadrivalent vaccine
[73]. As there has been no corresponding decrease in older
males and very few males have received the vaccine, the
authors attribute this decrease in young males to protection
via herd immunity. In Sweden, however, Leval et al.
reported decrease in genital warts amongst women but no
decrease in men since implementation of an opportunistic
program for females [74]. Although the model used for the
current assessment includes females only, the impact of
herd immunity on males was simulated by increasing over-
all genital warts incidence by multiplier of 2.0 or 2.2 and as-
suming quadrivalent vaccine efficacy to range from 20% to
90% of the cases that would normally be seen in men.
Multivariate probabilistic sensitivity analyses were con-
ducted to explore the combined effect of parameter un-
certainty using @Risk software (Palisade Corporation,
Ithaca, New York, USA). Distributions were assigned to
transition probabilities, vaccine effectiveness, proportion
of outcomes (genital warts, CIN and cancer) attributed
to each HPV type, screening effectiveness, costs, utilities
using normal distribution (limited from 0–1 for transi-
tion probabilities) when confidence intervals were avail-
able, otherwise, a uniform distribution was assigned
ranging from 25% below and above base case value
(Table 4). In total, 10,000 samples were generated from
the assigned distribution.
Table 4 Distributions used for probabilistic sensitivity
analyses
Variable names Distribution Distribution
parameters
Probability of transitioning between health states
HPVOnc to CIN1 Normal* 0.076 (S.D. 0.009) [75]
HPV low risk to CIN1 Normal* 0.036 (S.D.0.005) [76,77]
CIN1 low risk regression Normal* 0.5 (S.D. 0.145) [77]
CIN1 Onc Cured Normal* 0.5 (S.D. 0.145) [76-78]
CIN1 Onc to CIN2/3
progression
Normal* 0.13 (S.D. 0.021) [76,78]
CIN2/3 Cured Normal* 0.5 (S.D.0.058) [76,77]
HPV Onc regression Uniform† 0.375 - 0.625[79]
HPVOnc to CIN2/3
progression
Uniform† 0.008 - 0.013
(assumption)
HPV Low risk regression Uniform† 0.218 - 0.363
(assumption)




CIN1 treatment success Uniform† 0.95 -1[76]




Uniform† 0.9 -1 (assumption)
CIN2/3 treatment success Uniform† 0.9-1 (assumption)
Cervical cancer to death Uniform† 0.056 - 0.094[81]
Cervical cancer to cured Uniform† 0.184 - 0.307[81]
Utility data
No HPV Fixed (1) 1 [57,58]
HPV Fixed (1) 1 [57,58]
Death Fixed (0) 0
Genital Wart Uniform‡ 0.015 - 0.025 [58,82]
CIN1 detected Uniform‡ 0.010 - 0.016 [57,58]
CIN2/3 detected Uniform‡ 0.007 - 0.012 [57,58]
Cancer Uniform‡ 0.205 - 0.341 [57,58]
Cancer cured Uniform‡ 0.047 - 0.078 [57,58]
Screening effectiveness
CIN1 detected Normal§ 0.422 (S.D. 0.045) [81]
CIN2/3 detected Normal§ 0.554 (S.D. 0.045) [81]
Percentage estimated
positive Pap smear





















Normal|| 0.48 (S.D. 0.083) [25]
Table 4 Distributions used for probabilistic sensitivity
analyses (Continued)
HPV-6/11/16/18 vaccine
efficacy against other HPV onc




Normal|| 0.48 (S.D. 0.083) [25]
HPV-6/11/16/18 vaccine
efficacy against CIN1 and other
Normal|| 0.23 (S.D. 0.0715) [27]
HPV-16/18 AS04-adjuvanted
vaccine efficacy against CIN2+
Normal|| 0.68 (S.D. 0.092) [25]
HPV-6/11/16/18 vaccine
efficacy against CIN2+




Normal|| 0.98 (S.D. 0.065) [49,50]
HPV type distributions
Proportion of HPV Onc Uniform† 0.585 - 0. 975 [84]
Proportion of HPV-6/11
among warts in Canada
Uniform† 0.572 - 0.953 [84]
Proportion of HPV-16
and −18 among CIN1
in Canada
Uniform† 0.188 - 0.312 [84]
Proportion of HPV-16
and −18 among CIN2/3
Uniform† 0.437 - 0.729 [84]
Proportion of HPV-6
and −11 among CIN1
Uniform† 0.06 - 0.10 [84]
Proportion of HPV
10 types among CIN1
Uniform† 0.252 - 0.42 [84]
Proportion of HPV
10 types among CIN2/3
Uniform† 0.256 - 0.426 [84]
Proportion of HPV
10 types among CC
Uniform† 0.144 - 0.240 [84]
Proportion CIN1onc among
CIN1 (other being CIN1LR)




Uniform‡ $ 281 - $469
(assumption)
CC – Cervical cancer.
CIN – Cervical Intraepithelial Neoplasia.
HPV – Human papillomavirus.
Onc - oncogenic.
SD – Standard deviation.
* Normal distribution between 0 and 1 using as mean, the observed mean,
and as standard deviation, 25% of the difference between the minimum and
maximum value reported in the literature.
† Multiplied by a uniform distribution from 0.75 to 1.25 (with amaximum of 100%).
‡ Multiplied by uniform distribution from 0.75 – 1.25.
§ Normal distribution between 0 and 1 using as the mean: the observed mean
and as the standard deviation 25% of difference of the confidence interval.
|| Normal distribution with a mean and standard deviation reported in clinical
trials.
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http://www.biomedcentral.com/1471-2458/12/872In order to customize the model to each of the Canadian
provinces, a budget impact module that calculated the size
of the target population and the cost of vaccination was
constructed. It was linked to the cost-effectiveness model
in order to predict lifetime costs and outcomes. The target
population was based on the number of females in the
assumed target age group for each province (Table 1) in
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http://www.biomedcentral.com/1471-2458/12/872the 2011/12 school year based on age-specific population
data from Statistics Canada [85]. Two provinces, Alberta
and Quebec, had catch-up programs in the 2011/12
school year and these populations were also modelled. In
contrast to the cost-effectiveness analysis, coverage was
not expected to be 100%: the number of females vacci-
nated within each of these age groups was calculated using
expected coverage rates (Table 1). It was assumed that
provinces employed either a 3 dose or a 2 + 1 dosing strat-
egy (Table 1) based on current policies. In a 3 dose strat-
egy, the aim is to deliver three doses during the school
year, but it was assumed that vaccinees received an average
of 2.7 doses due to imperfect coverage. In a 2 +1 strategy,
the aim is to deliver two doses during the school year but
it was assumed that vaccinees received an average of 1.95
doses. All vaccinated females were assumed to receive a
follow-up booster dose 5 years later. The efficacy of a 2 + 1
dosing strategy is not officially approved for either vaccine
and efficacy data for this strategy is not yet available from
clinical trials. It was therefore assumed that the clinical ef-
ficacy of the 2 + 1 strategy was the same as that obtained
with the 3 dose strategy.
The total annual cost from the perspective of the
budget holder (i.e. the Department of Public Health) was
calculated using the cost of vaccine purchase and ad-
ministration. The net impact was calculated by subtract-
ing the cost of providing all vaccinated females with the
HPV-6/11/16/18 vaccine from the cost of providing all
with the HPV-16/18 AS04-adjuvanted vaccine. TheTable 5 Base case cost-effectiveness results for 100,000 wome
Outcome HPV-16/18 AS04-adjuvante
vaccine plus screening (A
Undiscounted
CIN1 cases 8 217
CIN2/3 cases 1 294
Genital warts cases 9 688
Cervical cancer cases 113
Cervical cancer deaths 38
Life Years 7 163 635
Quality adjusted life years (QALY) 7 163 094
Lifetime cost of strategy $127 212 309
Incremental cost per QALY gained
Discounted outcomes
Life Years 2 982 064
QALY 2 981 855
Lifetime cost of strategy $75 010 163
Incremental cost per QALY gained
A – Vaccine A: HPV-16/18 AS04-adjuvanted vaccine.
B - Vaccine B: HPV-6/11/16/18 vaccine.
QALY – Quality Adjusted Life Year.
Discount Rate – 3%.lifetime health care system costs associated with the
HPV-16/18 AS04-adjuvanted vaccine plus cervical can-
cer screening were compared to those associated with
the HPV-6/11/16/18 vaccine plus cervical cancer screen-
ing. The total cost of each strategy included the health
care costs incurred by those receiving vaccination plus
cervical cancer screening as well as those receiving cer-
vical cancer screening only. The lifetime number of cer-
vical cancer events experienced in the cohort of the
assumed target population, including both vaccinated




The results of the base case cost-effectiveness analysis for
a cohort of 100,000 Canadian females across a lifetime
time horizon are summarized in Table 5. Overall, vaccin-
ation with the HPV-16/18 AS04-adjuvanted vaccine was
predicted to prevent 803 additional cases of CIN1, 651
additional cases of CIN2/3, 48 additional cases of cervical
cancer, and 16 additional cervical cancer deaths. The
HPV-6/11/16/18 vaccine on the other hand was predicted
to prevent 6,933 more cases of genital warts in females.
Since males are not modelled in this static simulation, the
base case assumes no indirect benefit of vaccination in
men due to reduced transmission of the virus in the popu-
lation; reduction in genital warts cases amongst males is






outcomes (A – B)
9 020 −803
1 945 −651
2 755 6 933
161 −48
54 −16
7 163 268 367
7 162 817 276
$129 344 736 -$2 132 427
A Dominates B
2 981 994 70
2 981 854 1
$75 693 270 -$683 107
A Dominates B
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http://www.biomedcentral.com/1471-2458/12/872vaccine was therefore associated with more life years
gained than the HPV-6/11/16/18 vaccine, but the differ-
ence was offset to some degree when the utility decre-
ments of the disease states were taken into account.
Indeed, the HPV-16/18 AS04-adjuvanted vaccine was
associated with 1 additional discounted QALY gained
compared with the HPV-6/11/16/18 vaccine. Overall, the
lifetime cost associated with treatment of cervical disease
and genital warts outcomes from a health care system per-
spective was estimated to be lower with the HPV-16/18
AS04-adjuvanted vaccine than with the HPV-6/11/16/18
vaccine. In the base case, since the HPV-16/18 AS04-
adjuvanted vaccine was predicted to be the lower cost
strategy and to be associated with marginally more QALYs
gained, it dominated the HPV-6/11/16/18 vaccine from a
cost-effectiveness standpoint.
The estimated clinical and cost impact of vaccinating
with the HPV-16/18 AS04-adjuvanted vaccine and the
HPV-6/11/16/18 vaccine using base case assumptions for
each province is shown in Table 6. The model predicted
that the use of the HPV-16/18 AS04-adjuvanted vaccine
would prevent 0 (Prince Edward Island) to 32 (Quebec)
additional cases of cervical cancer compared with the
HPV-6/11/16/18 vaccine across the lifetime of the
females targeted for vaccination in one school year due
to the higher cross-protective efficacy observed in clinical
trials. These estimates of cases saved included cervical
cancers in both females who receive vaccination and
those who did not. The predicted short-term costs repre-
sent those incurred from the perspective of the budget







Vaccine A 223 71 23 8
Vaccine B 237 78 25 10
Difference (A- B) −14 −8 −2 −2 −
Undiscounted short-term
Vaccine A 8 862 430 3 431 536 1 071 737 1 039 079 673
Vaccine B 8 862 430 3 431 536 1 071 737 1 039 079 673
Difference (A-B) 0 0 0 0
Discounted long-term b
Vaccine A 71 372 551 15 984 442 4 131 005 2 865 649 1 85
Vaccine B 72 015 197 16 091 773 4 155 215 2 890 712 1 87
Difference (A-B) −642 645 −107 331 −24 210 −25 063 −15
Short-term budget impact: Considers 1 year of vaccine purchase and administration
Long-term budget impact: Considers lifetime costs to the health care system for th
includes both vaccinated and unvaccinated women.
CAD - Canadian dollars.
Vaccine A: HPV-16/18 AS04-adjuvanted vaccine.
Vaccine B: HPV-6/11/16/18 vaccine.
PEI – Prince Edward Island.since they are assumed to be priced equivalently. As
described above, prevention of additional cervical disease
was predicted to save more health care costs than pre-
vention of genital warts, and this was reflected in the
projections of long-term budget impact in Table 6.
Deterministic sensitivity analysis
The deterministic sensitivity analyses conducted with
the cost-effectiveness model illustrate the importance of
various inputs to the predicted relative clinical and eco-
nomic impact of the two vaccines. Table 7 shows the im-
pact of varying the degree of cross-protection that each
vaccine provides. When the difference in cross-
protection efficacy was reduced from the base case, the
predicted profile of the HPV-6/11/16/18 vaccine relative
to the HPV-16/18 AS04-adjuvanted vaccine improved.
When the difference in cross-protection efficacy be-
tween the HPV-16/18 AS04-adjuvanted vaccine and the
HPV-6/11/16/18 vaccine was assumed to be less than
16.5%, then the estimated costs saved and QALYs gained
by preventing genital warts with the HPV-6/11/16/18
vaccine more than offset the benefit of any additional
cervical disease predicted to be prevented by the HPV-
16/18 AS04-adjuvanted vaccine. The HPV-6/11/16/18
vaccine therefore dominated the HPV-16/18 AS04-
adjuvanted vaccine in these scenarios. When the differ-
ence in cross-protection efficacy between the HPV-16/
18 AS04-adjuvanted vaccine and the HPV-6/11/16/18
vaccine was assumed to be 16.5% or 30.5%, then the
QALYs gained by preventing cervical disease were pre-
dicted to be more than offset by the HPV-6/11/16/18r 10 provinces in Canada
undland Nova
Scotia
Ontario PEI Quebec Saskatchewan
ervical cancer cases
6 11 269 2 208 11
7 13 288 2 240 13
1 −2 −19 0 −32 −2
budget impact (CAD)
843 1 244 617 11 758 847 173 180 14 284 003 1 426 186
843 1 244 617 11 758 847 173 180 14 284 003 1 426 186
0 0 0 0 0 0
udget impact (CAD)
8 981 3 600 539 48 811 638 491 961 58 240 107 3 861 885
4 203 3 630 560 49 128 834 495 873 58 720 943 3 894 102
222 −30 021 −317 196 −3 912 −480 836 −32 217
costs.
e cohort of women eligible for vaccination in the 2011–12 school year. This


















(A – B) (A – B) (A – B) (A – B)
A: 45.7; B: 51.9 −6.2 8 $628 335 −115 B Dominates A
A: 45.7; B: 32.5 13.2 −18 $28 868 −62 B Dominates A
A: 68.4; B: 51.9 16.5 −22 -$83 640 −52 $1 611
A: 82.4; B: 51.9 30.5 −42 -$530 970 −12 $43 499
Base Case:A:
68.4; B: 32.5
35.9 −48 -$683 107 1 A Dominates B
A: 45.7; B: 6.0 39.7 −52 -$771 520 10 A Dominates B
A: 82.4; B: 32.5 49.9 −67 -$1 130 437 41 A Dominates B
A: 68.4; B: 6.0 62.4 −83 -$1 483 495 73 A Dominates B
A: 82.4; B: 6.0 76.4 −102 -$1 930 825 113 A Dominates B
Cross-protection efficacy: Efficacy against CIN2/3+ outcomes attributed to non-vaccine oncogenic types.
A - Vaccine A: HPV-16/18 AS04-adjuvanted vaccine.
B - Vaccine B: HPV-6/11/16/18 vaccine.
QALY – Quality Adjusted Life Year.
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http://www.biomedcentral.com/1471-2458/12/872vaccine’s advantage in preventing genital warts. However,
the projected lifetime costs associated with the HPV-16/
18 AS04-adjuvanted vaccine were still lower in these
two scenarios. When the HPV-16/18 AS04-adjuvanted
vaccine was assumed to have a 35.9% or greater cross-
protection efficacy (as in the base case), then the pro-
jected lifetime costs were lower and the estimated
QALYs saved were greater compared with the HPV-6/
11/16/18 vaccine. In other words, the HPV-16/18 AS04-
adjuvanted vaccine was predicted to be better value for
money than the HPV-6/11/16/18 vaccine. In all sensitiv-
ity analyses, the vaccine with the highest cross-
protection efficacy was predicted to prevent the most
cases of cervical cancer.
Additional deterministic sensitivity analyses show the
impact of reducing the price per dose of the HPV-6/
11/16/18 vaccine, changing the assumed HPV distribu-
tion or altering the burden associated in genital warts
(Table 8). Reducing the price per dose of the HPV-6/
11/16/18 vaccine reduced the estimated discounted life-
time cost to the health care system associated with use
of that vaccine. When the HPV-16/18 AS04-adjuvanted
vaccine was priced at $100 per dose and the HPV-6/
11/16/18 vaccine was priced somewhere between $97
and $98 per dose, the discounted lifetime health care
costs associated with each vaccine were predicted to be
equivalent. Due to the minimal difference in QALYs
between the vaccines, when the price per dose of the
quadrivalent is reduced from $98 to $97, the bivalent
changes from dominating the quadrivalent to being a
relatively poor value for money at an incremental cost
per QALY of $145,773. Changing the data source for
the HPV distribution from Canadian to NorthAmerican values actually decreased the proportion of
cases of cervical cancer attributed to the HPV types
impacted by cross-protection. In this scenario, the
HPV-16/18 AS04-adjuvanted vaccine was therefore pre-
dicted to prevent 41 more cases of cervical cancer than
the HPV-6/11/16/18 vaccine, compared to 48 more
cases in the base case. This relative reduction in benefit
meant that the estimated QALYs saved using the HPV-
6/11/16/18 vaccine were greater than that of the HPV-
16/18 AS04-adjuvanted vaccine, although the lifetime
cost associated with the HPV-16/18 AS04-adjuvanted
vaccine was still lower. The remaining sensitivity ana-
lyses changed the burden associated with genital warts.
The HPV-6/11/16/18 vaccine became relatively more
attractive when the proportion of warts attributed to
HPV-6/11 or the incidence of genital warts was
increased, when the quality of life impact (disutility)
associated with genital warts was increased or when
protection against HPV-6/11 genital warts in men due
to herd immunity was simulated. Changing the cost of
treating genital warts impacted the predicted relative
lifetime costs associated with the two vaccines, but not
enough to give the HPV-6/11/16/18 vaccine an advan-
tage. In all of these analyses, the HPV-16/18 AS04-
adjuvanted vaccine was estimated to have an overall
lower lifetime cost than the HPV-6/11/16/18 vaccine,
except when the protection against HPV-6/-11 asso-
ciated genital warts in males due to herd immunity is
expected to be high (90%).
Probabilistic sensitivity analysis
The results of the probabilistic sensitivity analysis are
illustrated using the cost-effectiveness plane in Figure 3











(A – B) (A – B) (A – B)
Base Case −48 -$683 107 1 A Dominates B
Vaccine price
HPV-6/11/16/18 vaccine price
decreased to $98 per dose
−48 -$83 107 1 A Dominates B
HPV-6/11/16/18 vaccine price
decreased to $97 per dose
−48 $216 893 1 $145 773 B lower lifetime cost;
A saves more QALYs
HPV distribution
Changed to North American data −41 -$760 577 −13 $59 359 A lower lifetime cost;
B saves more QALYs
Proportion of 6 / 11 in genital
warts increased to 90%
−48 -$496 855 −19 $26 015 A lower lifetime cost;
B saves more QALYs
Impact of herd immunity on male genital wart lesions
Double incidence of GW, assume
herd immunity impact of 20%
−48 -$564 421 −8 $68 100 A lower lifetime cost;
B saves more QALYs
Double incidence of GW, assume
herd immunity impact of 30%
−48 -$461 020 −18 $25 388 A lower lifetime cost;
B saves more QALYs
Double incidence of GW, assume
herd immunity impact of 40%
−48 -$355 588 −28 $12 629 A lower lifetime cost;
B saves more QALYs
Double incidence of GW, assume
herd immunity impact of 50%
−48 -$248 084 −38 $6 481 A lower lifetime cost;
B saves more QALYs
Double incidence of GW, assume
herd immunity impact of 90%
−48 $203 554 −80 B Dominates A
Incidence of GW*2.2, assume
herd immunity impact of 20%
−48 -$538 277 −10 $52 037 A lower lifetime cost;
B saves more QALYs
Incidence of GW*2.2, assume
herd immunity impact of 30%
−48 -$414 878 −22 $18 739 A lower lifetime cost;
B saves more QALYs
Incidence of GW*2.2, assume
herd immunity impact of 40%
−48 -$288 911 −34 $8 473 A lower lifetime cost;
B saves more QALYs
Incidence of GW*2.2, assume
herd immunity impact of 50%
−48 -$160 318 −46 $3 468 A lower lifetime cost;
B saves more QALYs
Incidence of GW*2.2, assume
herd immunity impact of 90%
−48 $381 563 −96 B Dominates A
Genital warts incidence
+25% −48 −449 523 −20 $22 485 A lower lifetime cost; B
saves more QALYs
+10% −48 −589 284 −7 $82 535 A lower lifetime cost; B
saves more QALYs
−10% −48 −777 456 10 A Dominates B
−25% −48 −919 979 23 A Dominates B
Genital warts cost
Increased to 125% of base case −48 -$444 754 1 A Dominates B
Decreased to 75% of base case −48 -$924 966 1 A Dominates B
Genital warts disutility
Increased to 125% of base case −48 -$683 107 −21 $32 749 A lower lifetime costs;
B saves more QALYs
Decreased to 75% of base case −48 -$683 107 24 A Dominates B
0.041, Drolet et al. −48 -$683 107 −95
$7 170 A lower lifetime costs;
B saves more QALYs
A – Vaccine A - HPV-16/18 AS04-adjuvanted vaccine.
B - Vaccine B: HPV-6/11/16/18 vaccine.
QALYs – Quality adjusted life years.
* A Dominates B – HPV-16/18 AS04-adjuvanted vaccine associated with lower lifetime costs to the healthcare system than HPV-6/11/16/18 vaccine; HPV-16/18
AS04-adjuvanted vaccine also saves more QALYs than HPV-6/11/16/18 vaccine.



















Figure 3 Incremental cost effectiveness plane for vaccination of 100,000 12 year-olds with the HPV-16/18 AS04-adjuvanted vaccine
compared with the HPV-6/11/16/18 vaccine across a lifetime time horizon (discounted). Each dot on the graph represents the relative
discounted costs (per 100,000 Canadian dollars (CDN)) and discounted quality adjusted life years (QALY) of one out of the 10,000 completed
simulations. The difference in discounted costs and QALYs is calculated by subtracting the HPV-6/11/16/18 vaccine (Vaccine B) from the HPV-16/
18 AS04-adjuvanted vaccine (Vaccine A) values (e.g. A – B). Quadrant I contains scenarios where the HPV-16/18 AS04-adjuvanted vaccine is
associated with greater lifetime costs and more QALYs saved (0.3% of simulations). Quadrant II contains scenarios where the HPV-16/18 AS04-
adjuvanted vaccine is associated with lower lifetime costs and more QALYs saved (C is dominant: 48.7% of simulations). Quadrant III contains
scenarios where the HPV-6/11/16/18 vaccine is associated with greater lifetime costs and more QALYs saved (34.8% of simulations). Quadrant IV
contains scenarios where the HPV-6/11/16/18 vaccine is associated with lower lifetime costs and more QALYs saved (G is dominant: 16.3% of
simulations).
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sented by a dot. In 0.3% of the replicates, the HPV-16/
18 AS04-adjuvanted vaccine was predicted to have
greater lifetime costs and greater QALY benefit than the
HPV-6/11/16/18 vaccine (Quadrant I of figure). The
HPV-16/18 AS04-adjuvanted vaccine was predicted to
have lower lifetime costs and a greater lifetime benefit in
48.7% of scenarios (Quadrant II; the HPV-16/18 AS04-
adjuvanted vaccine is dominant). The opposite was true
in 16.3% of scenarios (Quadrant IV; the HPV-6/11/16/18
vaccine is dominant), while the HPV-6/11/16/18 vaccine
was predicted to have greater lifetime costs and greater
benefit in 34.8% of analyses. In other words, the QALY
benefit was estimated to be greater for the HPV-16/18
AS04-adjuvanted vaccine in 48.9% of scenarios and for
the HPV-6/11/16/18 vaccine in 51.1% of scenarios.
There were more scenarios where the lifetime costs
associated with the HPV-16/18 AS04-adjuvanted vaccine
were estimated to be lower than that of the HPV-6/11/
16/18 vaccine (83.5%).
Discussion
This analysis presents a comparison of the relative clin-
ical and economic benefit of the two HPV vaccines that
are licensed for use in Canada using a static Markov
model reproducing HPV disease in women. In the base
case analysis, compared with the HPV-6/11/16/18 vac-
cine, the HPV-16/18 AS04-adjuvanted vaccine isassociated with an overall greater reduction in cervical
cancer and precancerous lesions, and a greater number
of QALYs saved, for an overall lower lifetime cost to the
health care system. Hence, under base case assumptions,
the HPV-16/18 AS04-adjuvanted vaccine provides better
value for money than the HPV-6/11/16/18 vaccine. In-
deed, the difference in the discounted QALYs saved be-
tween the two vaccination strategies is small, and this
difference is greatly impacted in the sensitivity analyses.
The HPV-6/11/16/18 vaccine is associated with higher
QALYs saved when the relative cross-protection benefit
of the HPV-16/18 AS04-adjuvanted vaccine is reduced,
the proportion of genital warts due to HPV-6/11 is
increased, or the impact of genital warts on utility (the
disutility) is increased. In all scenarios, except where the
cross-protection benefit of the HPV-16/18 AS04-
adjuvanted vaccine is assumed to be lower than the
HPV-6/11/16/18 vaccine, vaccination with the HPV-16/
18 AS04-adjuvanted vaccine is associated with an overall
lower lifetime cost to the health care system when the
vaccines are priced at parity. In the probabilistic sensitiv-
ity analyses, the HPV-16/18 AS04-adjuvanted vaccine
provides more QALY benefit than the HPV-6/11/16/18
vaccine in 49.2% of scenarios, while it has lower relative
lifetime costs in 83.5% of scenarios. The budget impact
model analyses illustrate how the clinical and cost differ-
ences between the vaccines may manifest using estimated
target populations in each of the Canadian provinces.
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Two other publications have compared the costs and
benefits of the HPV-16/18 AS04-adjuvanted vaccine and
the HPV-6/11/16/18 vaccine while considering the
current cross-protection efficacy data from clinical trials.
Capri and colleagues used a population model and esti-
mated that the additional cross-protection benefit asso-
ciated with the HPV-16/18 AS04-adjuvanted vaccine
would prevent an additional 295 cases of cervical cancer
in the Italian population compared with the HPV-6/11/
16/18 vaccine [39]. They also concluded that the health
care cost savings associated with preventing additional
precancerous and cancerous lesions would offset the
savings associated with preventing genital warts. Jit and
colleagues [41] used a dynamic transmission model to
estimate the impact of the vaccine in the United King-
dom looking at cervical cancer, genital warts and other
HPV associated cancers. In their analysis, the costs and
QALYs saved associated with preventing genital warts
outweighed the costs and QALYs saved associated with
preventing cervical cancer. The difference in the results
between the British analysis described above and this
Canadian analysis may be because the difference in
cross-protection benefit was assumed to be smaller than
in this analysis: Jit et al. [41] assumed 47.7% and 24.3%
cross-protection efficacy for the HPV-16/18 AS04-
adjuvanted vaccine and the HPV-6/11/16/18 vaccine re-
spectively for all cervical outcomes. In addition, the inci-
dence of genital warts was assumed to be more than
double the incidence in our analysis. The United King-
dom study used to parameterize the model by Jit et al.
[41] estimated annual genital warts incidence (new and
recurrent cases) at 289/100,000 population [86], whereas
the Canadian study used for this analysis estimated it at
126/100,000 [44]. Finally, Jit et al. used a higher discount
rate (3.5% compared to 3.0% in our analysis) which will
impact the costs accrued at older ages (e.g. cervical can-
cer treatment costs) more than those accrued at younger
ages (e.g. genital warts treatment costs).
In a third publication, Demarteau and Standaert con-
ducted analyses using the model in this publication
adapted to France, Ireland, and Italy to determine the im-
pact of cross-protection on the relative cost-effectiveness
of a hypothetical bivalent and a hypothetical quadrivalent
vaccine. The bivalent vaccine was assumed to prevent
95% of HPV types −16 and −18 infection while the
quadrivalent prevent 95% of HPV type −16, -18, -6, and
−11 infections. Both vaccines were assumed to provide
lifetime protection against HPV-16, while efficacy against
HPV-18 was assumed to wane after 10 years. With the
quadrivalent vaccine, efficacy against HPV-6 and −11 was
also assumed to wane after 10 years. The discounted
incremental cost per QALY of the bivalent vaccine com-
pared to the quadrivalent vaccine fell below a cost-effectiveness threshold of the gross domestic product
(GDP) when the bivalent provided an additional 22% in
cross-protection efficacy in France, 48% in Ireland, and
43% in Italy. The WHO suggests that interventions with
an incremental cost per QALY below this threshold be
considered as highly cost-effective [87].
Limitations
This analysis is subject to limitations common to all
decision analytic models in that it combines data from
numerous sources, requires structural and data assump-
tions, and can be subject to certain biases. Given the
uncertainty in epidemiological data, a number of simpli-
fying assumptions were made. Co-infection with mul-
tiple oncogenic HPV types for example is not explicitly
modeled. Patterns of HPV infection and cervical cancer
screening practices were modeled based on average Can-
adian data and may therefore vary from actual practices
in each of the provinces. The health economic model
that generates estimates of lifetime costs and clinical im-
pact in this analysis is a static Markov model reprodu-
cing disease burden in women, and as such does not
account for the benefits associated with herd immunity
of female vaccination on men. In terms of cervical can-
cer outcomes, the impact of vaccinating females may
therefore be underestimated for both vaccines. We did
not directly model outcomes in men who may benefit
from a reduction in transmission of HPV-6/11 and an
associated reduction in genital warts. We have
attempted to simulate the impact of this in a number of
sensitivity analyses, however, this indirect benefit can
only be estimated with a dynamic model.
In this analysis, it was assumed that both vaccines pro-
vided lifetime protection, but the true duration of pro-
tection of the vaccines is not yet known. In a
comparative clinical immunogenicity/safety study of the
HPV-16/18 AS04-adjuvanted vaccine and the HPV-6/
11/16/18 vaccine, the HPV-16/18 AS04-adjuvanted vac-
cine induced superior neutralizing antibody response
compared to the HPV-6/11/16/18 vaccine for both
HPV-16 and −18 in 18–45 year old women up to 24
months after first injection [88,89]. Although an im-
munological correlate of protection is not currently
defined, differences in the magnitude of the immune
responses between vaccines may represent determinants
of duration of protection [88]. If one of the vaccines pro-
vided less than lifetime protection, the projected impact
on lifetime cervical cancer cases would decrease while
the lifetime cost associated with that vaccination strategy
would increase. While we have attempted to identify two
publications with comparable estimates of cross-
protective efficacy for the 10 HPV types of interest, there
is no single trial that directly compares the cross-
protective efficacy of the bivalent and quadrivalent
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HPV types is reported as a composite endpoint in clin-
ical trials and is captured as such in our model. Type-
specific cross-protection efficacy has not been reported
for both vaccines; if efficacy varies by type then the over-
all cross-protection efficacy will depend on type-specific
HPV prevalence which may vary by population. The
combined data are the most similar across the two vac-
cines and also provide more robust estimates for the
rarer outcomes such as CIN lesions.
HPV infection may cause cancers at other sites in
women, including anal, vaginal, vulvar, and head and
neck cancers, and these outcomes were not modeled in
this analysis. Jit and colleagues [41] demonstrated in
their United Kingdom analysis that accounting for the
protection against the other HPV-related cancers does
impact the relative value of the vaccines depending on
assumptions about the efficacy of the vaccines in pre-
venting HPV infections associated with these cancers. If
both vaccines are assumed to have equivalent efficacy in
preventing HPV infections leading to these outcomes,
then their exclusion from the analysis does not impact
the conclusion about the relative value of the HPV-16/
18 AS04-adjuvanted vaccine and the HPV-6/11/16/18
vaccine. If one vaccine is assumed to provide superior
protection against these other cancers, then the exclu-
sion from the analysis will bias results.Conclusions
Based on our model, implementation of an HPV-
immunization program in Canada using the HPV-16/18
AS04-adjuvanted vaccine is expected to be associated
with a lower lifetime cost and a similar number of
QALYs saved compared to the HPV-6/11/16/18 vaccine
under base case assumptions. Overall, the HPV-16/18
AS04-adjuvanted vaccine reduced additional cervical
cancer disease morbidity and mortality compared with
the HPV-6/11/16/18 vaccine but had no impact on the
morbidity associated with genital warts. From an eco-
nomic perspective, the lifetime relative costs and QALYs
saved by implementing each of the vaccines will depend
on the assumptions about the extent of cervical disease
caused by HPV types prevented by cross-protection, and
the burden of genital warts caused by HPV-6/11. The
results of this analysis may therefore differ in countries
with a different portion of cervical disease attributed to
HPV types impacted by cross-protection or a higher
genital warts burden.Endnotes
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